Related Experiment Video
Updated: May 21, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Switchable Enzyme-Regulated ECM-Integrin-Cholesterol Signaling Orchestrate PD-L1 Dual Destabilization for Boosting
Wenbo Yin1,2, Yue Wang3, Zonghang Liu4
1State Key Lab of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
Abstract:
Although PD-1/PD-L1 blockade therapy has shown clinical success, its efficacy in solid tumors remains limited by the immunosuppressive tumor microenvironment. The tumor extracellular matrix (ECM), which forms a dense physical barrier and activates integrin-mediated mechanotransduction to upregulate PD-L1, while cholesterol-enriched membrane domains stabilize integrin clustering and PD-L1 localization, forming a self-reinforcing ECM-integrin-cholesterol signaling network that drives immune evasion. Here, we designed a switchable natural enzyme nanoplatform with dual safety locks, co-delivering papain and cholesterol synthesis inhibitor simvastatin to disrupt this network at multiple levels. Papain remains inactive during systemic circulation and intracellular trafficking, ensuring biosafety, but is selectively activated by tumor-released glutathione and boosted by localized photothermal heating to precisely degrade ECM, suppressing integrin signaling and PD-L1 transcription, while simvastatin-driven cholesterol depletion amplifies this effect by destabilizing integrin clusters and promoting PD-L1 degradation. Combined with phototherapy-induced immunogenic cell death, this strategy remodels ECM, enhances T cell infiltration, overcomes checkpoint blockade resistance, and eradicates advanced tumors (∼500 mm3).
Insights
This study introduces a novel nanoplatform that degrades the tumor extracellular matrix and depletes cholesterol to overcome resistance to PD-1/PD-L1 cancer immunotherapy, leading to tumor eradication.
Area of Science:
- Biomedical Engineering
- Cancer Immunology
- Nanomedicine
Background:
- Immunosuppressive tumor microenvironment limits PD-1/PD-L1 blockade therapy efficacy in solid tumors.
- Tumor extracellular matrix (ECM), integrin signaling, and cholesterol promote immune evasion by upregulating PD-L1.
- A self-reinforcing ECM-integrin-cholesterol network drives resistance to cancer immunotherapy.
Purpose of the Study:
- To design a switchable nanoplatform to disrupt the ECM-integrin-cholesterol signaling network.
- To overcome resistance to PD-1/PD-L1 blockade therapy in solid tumors.
- To enhance T cell infiltration and eradicate advanced tumors.
Main Methods:
- Developed a nanoplatform co-delivering papain (enzyme) and simvastatin (cholesterol inhibitor).
- Papain activated by tumor glutathione and photothermal heating to degrade ECM and suppress PD-L1.
- Simvastatin depleted cholesterol to destabilize integrin clusters and promote PD-L1 degradation.
- Combined therapy with phototherapy-induced immunogenic cell death.
Main Results:
- The nanoplatform successfully degraded ECM, suppressed integrin signaling, and reduced PD-L1 levels.
- Simvastatin enhanced the therapeutic effect by depleting cholesterol and destabilizing integrin clusters.
- Combined therapy remodeled the tumor microenvironment, increasing T cell infiltration.
- Achieved complete eradication of advanced tumors (approximately 500 mm³).
Conclusions:
- The designed nanoplatform effectively disrupts the immunosuppressive ECM-integrin-cholesterol network.
- This multi-pronged strategy overcomes resistance to PD-1/PD-L1 blockade and enhances immunotherapy efficacy.
- The approach shows promise for treating advanced solid tumors by remodeling the tumor microenvironment and promoting tumor eradication.
More Related Videos
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
